SUN PHARMA ADV.RES.CO.LTD (SPARC) financials

SUN PHARMA ADV.RES.CO.LTD (SPARC) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products.[1]

Market Cap: ₹6,122Cr.
Current Price: ₹189
Stock P/E: 3.84
ROE: 281%
ROCE: 165%
Book Value: ₹41.1
Dividend Yield: 0.00%
52W High / Low: ₹289/108

In Jun 2026, SUN PHARMA ADV.RES.CO.LTD (SPARC) reported sales ₹40 Cr and net profit ₹-21 Cr.

Annual TTM: sales ₹1,909 Cr, net profit ₹1,583 Cr.

Shareholding: Promoters 65.68% (Sep 2026), FIIs 3.74% (Sep 2026), DIIs 0.11% (Sep 2026), Public 30.48% (Sep 2026), No. of Shareholders 1,41,992% (Sep 2026).

SPARC quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	13	15	27	10	8	8	1,853	40
Expenses	117	89	81	62	74	65	80	74
Operating Profit	-104	-74	-54	-52	-66	-57	1,773	-34
OPM %	-808%	-499%	-198%	-543%	-838%	-673%	96%	-86%
Other Income	0	0	0	9	0	-12	2	24
Interest	1	3	5	6	8	9	12	8
Depreciation	3	3	3	3	3	3	2	2
Profit before tax	-108	-80	-61	-52	-76	-81	1,761	-21
Tax %	0%	0%	0%	0%	0%	0%	0%	0%
Net Profit	-108	-80	-61	-52	-76	-81	1,761	-21
EPS in Rs	-3.32	-2.46	-1.88	-1.60	-2.34	-2.48	54.26	-0.65
Raw PDF	—	—	—	—	—	—	—	—

SPARC profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	77	253	137	239	76	72	1,879	1,909
Expenses	387	388	324	453	479	399	281	294
Operating Profit	-310	-135	-187	-214	-404	-327	1,598	1,616
OPM %	-404%	-53%	-136%	-90%	-534%	-456%	85%	85%
Other Income	10	5	7	11	29	2	-2	13
Interest	3	11	13	8	2	9	34	36
Depreciation	9	11	10	12	12	11	10	10
Profit before tax	-312	-151	-203	-223	-388	-345	1,552	1,583
Tax %	0%	0%	0%	0%	0%	0%	0%	—
Net Profit	-312	-151	-203	-223	-388	-345	1,552	1,583
EPS in Rs	-11.92	-5.77	-7.48	-6.86	-11.96	-10.64	47.83	48.79
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	—

SPARC balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	26	26	26	27	32	32	32	32
Reserves	270	-45	-194	4	480	92	-253	1,301
Borrowings	2	67	236	79	16	56	265	559
Other Liabilities	101	224	162	170	302	305	284	275
Total Liabilities	398	273	230	280	830	486	329	2,168
Fixed Assets	58	104	91	92	106	103	95	85
CWIP	24	32	5	26	27	44	54	72
Investments	211	8	6	12	291	2	0	0
Other Assets	106	128	127	150	406	338	179	2,011
Total Assets	398	273	230	280	830	486	329	2,168

SPARC cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	-172	-211	-152	-208	-69	-429	-362	-239
Cash from Investing Activity	-102	155	2	-29	-548	391	158	-24
Cash from Financing Activity	274	55	159	229	617	43	201	262
Net Cash Flow	0	0	9	-8	-1	4	-4	-1
Free Cash Flow	-184	-264	-153	-233	-84	-455	-372	-262
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	111%	65%	111%	114%	35%	105%	114%	-17%

SPARC shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	65.68%	65.68%	65.67%	65.67%	65.67%	65.67%	65.68%	65.68%
FIIs	2.23%	1.45%	1.47%	1.76%	2.04%	2.04%	3.90%	3.74%
DIIs	0.64%	1.13%	0.97%	1.05%	0.78%	0.88%	0.09%	0.11%
Public	31.47%	31.76%	31.88%	31.52%	31.51%	31.41%	30.34%	30.48%
No. of Shareholders	1,31,034	1,42,864	1,40,724	1,36,997	1,44,810	1,40,625	1,41,957	1,41,992

SPARC key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	20	76	25	74	50	75	82	2
Inventory Days	0	0	0	0	—	—	—	—
Days Payable	—	—	—	—	—	—	—	—
Cash Conversion Cycle	20	76	25	74	50	75	82	2
Working Capital Days	-98	-842	-268	-301	-193	-746	-1,778	214
ROCE %	-62%	-183%	-242%	-218%	-67%	-109%	-298%	165%

SPARCUpdated 19 Oct 2026, 2:01

Sun Pharma Adv.res.co.ltd

SPARCUpdated 19 Oct 2026, 2:01

Market Cap

₹6,122Cr.

Current Price

₹189

High / Low

₹289/108

Stock P/E

3.84

ROE281%

ROCE165%

Book Value₹41.1

Face Value₹1.00

Dividend Yield0.00%

About

Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products.[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Net Profit	EPS (₹)
Jun 2023	24	0	126	10	3	-95	-95	-2.94
Sep 2023	21	0	113	8	3	-86	-86	-2.66
Dec 2023	14	0	116	6	3	-100	-100	-3.07
Mar 2024	17	1	124	4	3	-107	-107	-3.29
Jun 2024	17	1	112	2	3	-97	-97	-2.98
Sep 2024	13	1	117	0	3	-108	-108	-3.32
Dec 2024	15	3	89	0	3	-80	-80	-2.46
Mar 2025	27	5	81	0	3	-61	-61	-1.88
Jun 2025	10	6	62	9	3	-52	-52	-1.6
Sep 2025	8	8	74	0	3	-76	-76	-2.34
Dec 2025	8	9	65	-12	3	-81	-81	-2.48
Mar 2026	1853	12	80	2	2	1761	1761	54.26
Jun 2026	40	8	74	24	2	-21	-21	-0.65

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	156	0	191	3	7	-40	0	-40	-1.6
Mar 2016	161	2	224	3	8	-70	0	-70	-2.83
Mar 2017	181	2	304	14	8	-119	0	-119	-4.82
Mar 2018	78	0	321	54	8	-197	0	-197	-7.85
Mar 2019	183	0	334	14	8	-145	0	-145	-5.55
Mar 2020	77	3	387	10	9	-312	0	-312	-11.92
Mar 2021	253	11	388	5	11	-151	0	-151	-5.77
Mar 2022	137	13	324	7	10	-203	0	-203	-7.48
Mar 2023	239	8	453	11	12	-223	0	-223	-6.86
Mar 2024	76	2	479	29	12	-388	0	-388	-11.96
Mar 2025	72	9	399	2	11	-345	0	-345	-10.64
Mar 2026	1879	34	281	-2	10	1552	0	1552	47.83
TTM	1909	36	294	13	10	1583	—	1583	48.79

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	65.68%
FIIs	3.74%
DIIs	0.11%
Public	30.48%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Dec 2023	65.68%	3.3%	0.67%	30.36%
Mar 2024	65.68%	3.24%	0.67%	30.41%
Jun 2024	65.68%	2.64%	0.17%	31.51%
Sep 2024	65.68%	2.15%	0.21%	31.96%
Dec 2024	65.68%	2.23%	0.64%	31.47%
Mar 2025	65.68%	1.45%	1.13%	31.76%
Jun 2025	65.67%	1.47%	0.97%	31.88%
Sep 2025	65.67%	1.76%	1.05%	31.52%
Dec 2025	65.67%	2.04%	0.78%	31.51%
Mar 2026	65.67%	2.04%	0.88%	31.41%
Jun 2026	65.68%	3.9%	0.09%	30.34%
Sep 2026	65.68%	3.74%	0.11%	30.48%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	24	76	4	39	143	67	0	0	76	143
Mar 2016	24	8	56	75	163	70	1	0	92	163
Mar 2017	25	133	3	111	273	69	1	10	192	273
Mar 2018	25	160	2	122	309	52	3	108	146	309
Mar 2019	26	270	2	101	398	58	24	211	106	398
Mar 2020	26	-45	67	224	273	104	32	8	128	273
Mar 2021	26	-194	236	162	230	91	5	6	127	230
Mar 2022	27	4	79	170	280	92	26	12	150	280
Mar 2023	32	480	16	302	830	106	27	291	406	830
Mar 2024	32	92	56	305	486	103	44	2	338	486
Mar 2025	32	-253	265	284	329	95	54	0	179	329
Mar 2026	32	1301	559	275	2168	85	72	0	2011	2168

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	-41	53	-1	11
Mar 2016	-44	-13	51	-7
Mar 2017	-128	-7	194	60
Mar 2018	-183	-105	224	-63
Mar 2019	-172	-102	274	0
Mar 2020	-211	155	55	0
Mar 2021	-152	2	159	9
Mar 2022	-208	-29	229	-8
Mar 2023	-69	-548	617	-1
Mar 2024	-429	391	43	4
Mar 2025	-362	158	201	-4
Mar 2026	-239	-24	262	-1

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	47	21	78	82	20	76	25	74	50	75	82	2
Inventory Days	0	0	0	0	0	0	0	0	—	—	—	—
Days Payable	—	—	—	—	—	—	—	—	—	—	—	—
Cash Conversion Cycle	47	21	78	82	20	76	25	74	50	75	82	2
Working Capital Days	20	-161	-60	-232	-98	-842	-268	-301	-193	-746	-1,778	214
ROCE %	-32%	-71%	-94%	-143%	-62%	-183%	-242%	-218%	-67%	-109%	-298%	165%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of SUN PHARMA ADV.RES.CO.LTD (SPARC)?

The reported market capitalisation for SUN PHARMA ADV.RES.CO.LTD (SPARC) is ₹6,122Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of SPARC?

The current price shown for SUN PHARMA ADV.RES.CO.LTD (SPARC) on Fincrux is ₹189 with a 52-week high/low of ₹289/108.

What is the P/E ratio of SUN PHARMA ADV.RES.CO.LTD (SPARC)?

The stock P/E for SUN PHARMA ADV.RES.CO.LTD (SPARC) is 3.84 on Fincrux, with ROE at 281% and ROCE at 165%.

What were SPARC latest quarterly results?

For Jun 2026, SUN PHARMA ADV.RES.CO.LTD (SPARC) reported sales ₹40 Cr and net profit ₹-21 Cr (figures in ₹ crore unless noted).

What are SPARC annual sales and net profit?

For TTM, SUN PHARMA ADV.RES.CO.LTD (SPARC) shows sales of ₹1,909 Cr and net profit of ₹1,583 Cr on the Fincrux profit & loss statement.

Who owns SUN PHARMA ADV.RES.CO.LTD (SPARC)?

Latest shareholding for SUN PHARMA ADV.RES.CO.LTD (SPARC) on Fincrux: Promoters 65.68% (Sep 2026), FIIs 3.74% (Sep 2026), DIIs 0.11% (Sep 2026), Public 30.48% (Sep 2026), No. of Shareholders 1,41,992% (Sep 2026).

Where can I find SUN PHARMA ADV.RES.CO.LTD (SPARC) financials?

SUN PHARMA ADV.RES.CO.LTD (SPARC) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show SPARC balance sheet and cash flow?

Yes. The SUN PHARMA ADV.RES.CO.LTD (SPARC) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 19 October 2026 at 2:01